

NO<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)SO<sub>2</sub>R<sup>4'</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, R<sup>4</sup>, whereby two substituents at R<sup>2</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

4. Benzimidazoles according to claim 1, wherein  
R<sup>3</sup> means one or two substituents, which, independently of one another, can be:  
hydrogen, F, Cl, Br,  
XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,  
XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>,  
XCN, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>,  
NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>N<sup>4'</sup>,  
XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)SO<sub>2</sub>R<sup>4'</sup>,  
XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, or R<sup>4</sup>, whereby two  
substituents R<sup>3</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl.

5. Benzimidazoles according to claim 1, wherein  
R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, C<sub>1-4</sub>  
alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-6</sub> cycloalkyl),  
phenyl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby  
the phenyl and heteroaryl groups can be substituted with one or two  
substituents from the group that consists of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, OCH<sub>3</sub>,  
OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>,  
and in addition in a 5-membered cycloalkyl ring, a ring  
member can be an N or an O, and in a 6-membered cycloalkyl ring, one or  
two ring members can be N and/or O, whereby ring nitrogens optionally can  
be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl.

Sub  
C3  
cont.

6. Benzimidazoles according to claim 1, wherein  $R^5$  and  $R^{5'}$ , independently of one another, can be  $C_{1-6}$  alkyl, whereby a carbon atom can be exchanged for O, NH, N  $C_{1-3}$  alkyl, N  $C_{1-3}$  alkanoyl,  $C_{3-7}$  cycloalkyl- $C_{0-3}$  alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl, whereby the mentioned  $C_{1-6}$  alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from N, S or O, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of  $CF_3$ , OH, O  $C_{1-3}$  alkyl, and the previously mentioned heteroaryl groups with one or two substituents that consist of F, Cl,  $CF_3$ ,  $CH_3$ ,  $C_2H_5$ ,  $OCH_3$ ,  $OC_2H_5$ , or  $R^5$  and  $R^{5'}$  together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy- $C_{0-2}$  alkyl,  $C_{1-4}$  alkoxy-carbonyl, aminocarbonyl or phenyl.

7. Benzimidazoles according to claim 1, wherein

A means  $C_{1-10}$  alkanediyl,  $C_{2-10}$  alkenediyl,  $C_{2-10}$  alkinediyl, ( $C_{0-5}$  alkanediyl- $C_{3-7}$  cycloalkanediyl- $C_{0-5}$  alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, or in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH, N  $C_{1-3}$  alkyl, or N  $C_{1-3}$  alkanoyl.

Sub  
C3  
cont.

8. Benzimidazoles according to claim 1, wherein  
B means COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH,  
CONHOR<sup>5</sup> or tetrazolyl,  
in each case bonded to a carbon atom of group A.

9. Benzimidazoles according to claim 1, wherein  
X means a bond or methylene.

10. Benzimidazoles according to claim 1, wherein  
Y means O.

Sub  
C5

12. 6-[[2-Phenyl-1-(3-pyridyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-fluoro-phenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-methoxyphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]-hexanoic acid methyl ester

6-[[2-(4-bromophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-[4-(trifluoromethyl)phenyl]-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[[(4-chlorophenyl)sulfonyl]amino]-1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[[(4-chlorophenyl)sulfonyl]amino]-2-(4-fluorophenyl)-1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

4-[[5-[[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]butanoic acid methyl ester

5-[[5-[[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5-[[5-[[[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

6-[[5-[[[(4-(trifluoromethyl)phenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[[(4-chlorophenyl)sulfonyl]methylamino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[1-(3-fluorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-nitrophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

N-(cyclopropylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(cyclopropylmethoxy)-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]-hexanamide

N-isobutoxy-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(3-methoxypropyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-morpholin-1-ylhexan-1-one

N,N-di(-2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopentyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-2-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-3-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N,N-dimethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N,N-diethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-isobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-cyclopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-cyclobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-tert-butyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

(R)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]1-(2-methoxymethyl)-pyrrolidin-1-ylhexan-1-one

N-(3-imidazol-1-yl-propyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

~~N-(2-pyridin-2-ylethyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide~~

~~N-(3-methoxypropyl)-6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]heptanamide~~

~~6-[[1-(4-methylphenyl)-2-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[2-(3-indolyl)-1-(4-methylphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(2-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(3-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(5-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester~~

~~6-[[1-(4-methylphenyl)-2-(3-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester,~~

~~each a compound of claim 1.~~

13. Use of a compound according to claim 1 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

14. Pharmaceutical agent, wherein it contains one or more compounds according to claim 1 and one or more vehicles.

Int  
Bz  
cont

17.

R<sup>2</sup>

Use according to claim 15, whereby in general formula II, means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl group or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,

XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>,

XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>,

XCONR<sup>4</sup>R<sup>4'</sup>,

XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>,

SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>,

XNHSO<sub>2</sub>R<sup>4</sup>,

XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>), XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>,

XNHCONHR<sup>4</sup>, R<sup>4</sup>,

whereby two substituents at R<sup>2</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.

18. Use according to claim 15, whereby in general formula II

R<sup>3</sup> stands for one or two substituents, which independently of one another, mean:

hydrogen,

F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>,

XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>,

XCN, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>,

XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>),

XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, or R<sup>4</sup>, whereby two substituents

R<sup>3</sup>, if they are in ortho-position to one another, can be linked to one another

in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.

Sub  
B2  
cont

19. Use according to claim 15, whereby in general formula II

$R^4$  and  $R^4$ , independently of one another, mean  $CF_3$ ,  $C_2F_5$ ,  $C_{1-4}$

alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{3-6}$  cycloalkyl, ( $C_{1-3}$  alkyl- $C_{3-6}$  cycloalkyl),  $C_{1-3}$  alkylaryl,  $C_{1-3}$  alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ ,  $C_2F_5$  or else can carry an annelated methanediylbisoxo or ethane-1,2-diylbisoxo group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl.

A3

20. Use according to claim 15, whereby in general formula II

$R^5$  and  $R^5$ , independently of one another, can be  $C_{1-6}$  alkyl,

whereby a carbon atom can be exchanged for O, NH, N  $C_{1-3}$  alkyl, N  $C_{1-3}$  alkanoyl,  $C_{3-7}$  cycloalkyl- $C_{0-3}$  alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl, whereby the mentioned  $C_{1-6}$  alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from the group that consists of N, S or O,

whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of  $CF_3$ , OH, O  $C_{1-3}$  alkyl, and the previously mentioned heteroaryl groups can be substituted with one or two substituents that consist of F, Cl,  $CF_3$ ,  $CH_3$ ,  $C_2H_5$ ,  $OCH_3$ ,  $OC_2H_5$ ,



Sub  
B<sup>2</sup>  
cont

or R<sup>5</sup> and R<sup>5'</sup> together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>0-2</sub> alkyl, C<sub>1-4</sub> alkoxy-carbonyl, aminocarbonyl or phenyl.

A3

21. Use according to claim 15, whereby in general formula II  
A means C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), or (C<sub>0-5</sub> alkanediyl-heteroaryl-C<sub>0-5</sub> alkanediyl), whereby an optionally present heteroaryl group can be substituted with one or two substituents that consist of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, whereby in an aliphatic chain, a carbon atom or two carbon atoms can be exchanged for O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl, NSO<sub>2</sub> C<sub>1-3</sub> alkyl, and whereby alkyl or cycloalkyl parts can be substituted with up to two F atoms or one of the substituents that consists of OH, O C<sub>1-3</sub> alkyl, O C<sub>1-3</sub> alkanoyl, =O, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl) (C<sub>1-3</sub> alkanoyl), NHCOO C<sub>1-3</sub> alkyl, NHCONH C<sub>1-3</sub> alkyl, NHSO<sub>2</sub> C<sub>1-3</sub> alkyl, SH, S C<sub>1-3</sub> alkyl.
22. Use according to claim 15, whereby in general formula II  
B means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, or tetrazolyl, in each case bonded to a carbon atom of group A.
23. Use according to claim 15, whereby in general formula II,  
X means a bond or CH<sub>2</sub>.

24. Use according to claim 15, whereby in general formula II,  
Y means a bond, O, S, NH, NR<sup>4</sup>, NCOR<sup>4</sup> or NSO<sub>2</sub>R<sup>4</sup>.